US drug developer Affymax and Japanese drug major Takeda have reported strong data on their ongoing Phase II trial to assess the long-term safety and tolerability of anemia drug Hematide. Dosed once every four weeks, the agent successfully maintained mean hemoglobin levels between 11g/dL and 12g/dL for up to 18 months in hemodialysis patients who were previously treated with epoetin alfa, noted the firms, adding that Hematide appeared generally well-tolerated.
81 dialysis patients, originally enrolled in an open-label study to evaluate a switch from epoetin alfa to Hematide, were rolled over to the long-term Phase II trial, and then maintained on the agent for the duration of the follow-up study. The patients received intravenous Hematide once every four weeks for approximately 18 months, totaling 18 doses. Dosing was designed to maintain Hb between 10g/dL-12g/dL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze